做多

ACXP cheaper than the public offering

Acurx filed a provisional patent application with the U.S. Patent and Trademark Office for use of ibezapolstat to treat C. difficile Infection (CDI) while reducing recurrence of infection and improving the health of the gut microbiome.

In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI.

The Company successfully completed Phase 1 and Phase 2a clinical trials of ibezapolstat and in the second half of 2021.
(prnewswire.com)

TopgOptions

DAILY PRIVATE HIGH-CONVICTION OPTIONS SIGNALS: patreon.com/PremiumOptionsSignals
Trading COURSE bit.ly/tradex
RESULTS bit.ly/TG99x
CRYPTOS partner.bybit.com/b/37880
BUY-SELL INDICATORS tradingindicators.store/

免责声明

这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。

TopgOptions